COVID-19 has arrived in Greater Minnesota – MinnPost

The first confirmed case of COVID-19 in Minnesota was announced on March 6 three months after China told to the world that patients in Wuhan were sick with pneumonia of unknown cause.

That first case was an older Ramsey County resident who had disembarked from the COVID-stricken Grand Princess cruise ship before it was quarantined. By the next week, a Carver County resident who had been in Europe was confirmed to have the virus. So was an Anoka County resident who had been traveling for work.

All three cases were in the Twin Cities metro area, which was the first place to be hit hard by the virus. Soon, medium-sized cities started to see coronavirus activity, as well as some rural parts of the state, particularly those with food processing outbreaks. But even months after the virus was first detected in the state, some rural parts of the state still saw low numbers of officially confirmed cases of the virus.

Thats started to change in recent weeks. Now some Greater Minnesota counties that had previously seen little confirmed coronavirus activity have started to see upticks in cases. And as of last weekend, with a confirmed case in Lake of the Woods County, every county in Minnesota has at least one case of COVID-19.

Article continues after advertisement

The novel coronavirus first appeared in the United States big cities, with a major outbreak in New York City back in April. In Minnesota, Hennepin and Ramsey counties were early centers of the outbreak.

Carrie Henning-Smith, an assistant professor in the University of Minnesotas School of Public Health said this may have given parts of rural America a false sense of security about the virus.

We know that COVID started in the U.S. as a distinctly urban phenomenon. We were first hearing about it in Seattle and New York and New Orleans,she said.

[Since] this took a long time to spread into some rural communities, I think that false sense of security may have become heightened. I think people looked around and said Im not sick, none of my neighbors have gotten sick lets move on and move back to life as normal, Henning-Smith said.

That may be changing in some areas now. Mahnomen County, in northern Minnesota, saw new cases per capita double between the second and third weeks of July, from 5.4 cases per 10,000 residents to 10.9 the same number of cases per capita as Hennepin County. In Koochiching County, on the Canadian border, new cases went from 10.3 per 10,000 people the week of the Fourth of July to 15 per 10,000 people the following week.

Source: Minnesota Department of Health

The county had seen some coronavirus activity prior to July, but really saw an increase from 3.3 new cases per 10,000 residents to 11.1 per 10,000 residents after the Fourth of July, according to Minnesota Department of Health data. In the most recent week of data, the number of new confirmed cases had slowed slightly, to 9.5 per 10,000 residents.

Our initial surge was a group of early 20-year-olds, Borgen said. Once the restrictions were released and folks were out at the bars, sporting events, recreation leagues, that kind of was the start of it for us.

Despite that cases had been present prior, hospitalizations had been few until recently, Borgen said. As of this week, four people were hospitalized with COVID-19 in Beltrami County.

Article continues after advertisement

Up until now, I think people felt a little more like If I get sick, Im not going to get very sick, Borgen said.

Some of the hospitalizations weve had were of people who were fairly young and healthy and its a small enough community that people learn pretty quickly whos in the hospital, even if we do our best to prevent any of that from coming through formal channels, she said.

While some in the community may not have seen COVID-19 as a big problem locally before, people are realizing this maybe is something that could impact me and my loved ones, Borgen said.

Before South Central Minnesotas Watonwan County saw an outbreak of COVID-19 last month, Community Health Services Manager Julia Whitcomb noted some belief in the community that the virus wasnt a concern in the area.

We did see some of those beliefs thinking its not here, so why do I need a mask or why do I need to follow social distancing, she said.

Concern heightened when cases climbed, but Whitcomb says some resumed lax mask-wearing behavior before the statewide mask order took effect on Saturday.

While geography is one factor that separates some Greater Minnesota residents feelings about the virus from others in the state, its not the only factor. The pandemic and the states handling of it has also become highly politicized, with people on the right side of the political spectrum tending to downplay the seriousness of the virus and the utility of interventions like face masks, while those on the left assume the opposite position.

Ahead of a public discussion of a local mask mandate in Alexandria that was scheduled before Gov. Tim Walzs mask mandate and took place this week, city officials said 286 people contacted the council in favor of a citywide mask mandate, while 463 people told the council they opposed such requirements.

Article continues after advertisement

Many who opposed the local mask mandate cited low case counts as rationale.

Its not necessary as we have very few cases in our city. I think it will just cause tension between people, wrote one who opposed a potential local mandate.

But politics also came into play.

One employee of a senior living center in town wrote in using their work email addresses opposing the mask mandate on political grounds: This pandemic has become more political than anything because it is forcing Americans to submit to rules/regulations that do not support the constitution that this great country was built on.

But as cases climb again nationally and public health officials initially often opposed to masks on the grounds of limited supplies of medical-grade ones come to a general consensus that they are effective in slowing the virus spread, that may be changing, too.

In a Harvard/Harris poll released this week, 79 percent of respondents said they supported a national mask mandate. A Fox poll of Minnesota residents released this month found the majority of respondents, 85 percent, felt strongly or somewhat favorable towards Minnesotans who wore face masks.

Article continues after advertisement

Particularly in summer, Greater Minnesota plays host to tourists from all over the state and country. Some residents worry about what that means when it comes to the accuracy of case counts in their areas.

Jen Sumption lives in Longville, Minnesota, home to the Woman Chain of Lakes, a big summer tourist destination in Cass County, where there have been 54 confirmed cases of COVID-19, according to MDH data, up from 12 a month ago.

Last week, she submitted a question to local radio station KAXE during a discussion with Lt. Gov. Peggy Flanagan to express concern about how case numbers are reported.

In rural Minnesota weve experienced an increase in cases as we saw an increase in out of town visitors, also the fishing opener and the Fourth of July weekend, she wrote.

If she were a Twin Cities or out-of-state resident who had been traveling up to lake country for generations, she said shed look at the states case map and might be likely to think Oh wow, Cass County, pretty consistently low, low-risk. Lets do it, she told MinnPost.

But she says that map isnt an accurate reflection of everyone whos been in Cass County: if people travel north and get sick, whether theyre tested in Cass County or back home, their result is associated with their home county.

Sumption told MinnPost that in a trip to town this week, she watched cars go by on Highway 84, the main drag through the town of 150.

I would say there were at least 20 to 25 cars that passed by where I could see their tags, and half were out-of-state, she said.

Shes concerned these travelers might see the low numbers in Cass County and let their guard down when they visit, believing the virus isnt in the community.

I think its a very false sense of security because the numbers dont actually represent the number of people who are really infected here, she said.

Walker Orenstein contributed to this report.

Read the rest here:

COVID-19 has arrived in Greater Minnesota - MinnPost

Africa in the news: New funding to fight COVID-19 in Africa, Somalias prime minister voted out, and political updates in Mali and Cte dIvoire -…

New loans and grants announced across the continent in response to COVID-19

The International Monetary Fund (IMF) approved the largest emergency loan in its history on Monday, providing South Africa $4.3 billion as it deals with its most prolonged recession since World War II. The IMF said that the loan will address the severe economic impact of the Covid-19 shock as well as the challenge of debt sustainability following the pandemic. South Africa had previously received $1 billion from the New Development Bank and $300 million from the African Development Bank, and it hopes to secure up to $2 billion from the World Bank.

The IMF also approved a debt relief package worth up to $24.97 million for Burundiwith the goal of assisting the countrytoservice its debt over the next couple years. The IMF has now awarded $251.24 million in debt relief to 28 developing countriesfrom itsCatastrophe Containment and Relief Trustthis year, fundingthatit hopes will free up fiscal space for public health and economic recovery needs.

Also this week,the African Development Bank (AfDB) approved a series of pandemic-related relief packages. The bank will provide $97.7 million to Rwanda and $37.1 million to Djibouti, whilealsoawarding grants (from the banks $10 billion COVID-19 Response Facility) of $69 million to Ghana, $31.6 million to Uganda, and $53.3 million each to Gambia, Liberia, and Sierra Leone.In other AfDB news, also this week,an independent probe announced that it has cleared AfDB presidentAkinwumiAdesina of misconduct, verifying the findings of anAfDB-led inquiry earlier this year.

On Saturday, July 25,theparliament of Somalia voted to remove Prime Minister Hassan AliKhairefrom office. One-hundred and seventy of the 178 members backed the motion,which statedthatKhairefailed to pave the way for democratic electionsincludingby improving the unstable security situation posed by alShabaabmilitants.President Mohamed AbdullahiMohamed has namedDeputy Prime Minister Mahdi MohamedGuledto serve as interim prime minister,according to the presidentsoffice.

Somalia has for years set its sights on one person, one vote,or a universal suffrage election, but hasnot been able to implement the policyinthe countrysprevious two elections. In 2012, 135 clan elders chose theparliament, who in turn selectedthepresident. In 2016,14,025 clan-representatives held a run-offelectionin an airport hangar at AdenAddeInternational AirportinMogadishu. Lawmakers had aimed to hold the countrys first fully democratic election in a half century in 2021, but now that goal is shrouded in uncertainty.

Khaire, also a Norwegian citizen and former primary school teacher in Norway, was new to politics when he was named prime minister in 2017. As a memberof theHawiyeclan, he had served to balancepower with theDarod presidentin accordance with the 4.5 clan system, which traditionally has led to theDarodand Hawiye clans each taking one of the highest two positions of office.He had previously worked at the British firmSoma Oil and Gas, where he was thedirector of the Africa department.

In Mali, the Economic Community of West African States (ECOWAS)regional bloc continued to work towardbrokering a political agreementbetween President Ibrahim BoubacarKetaand a protestingopposition. Earlier this week, theECOWAS negotiators recommended a dealwherein the 31 candidates elected to the countrys parliament earlier this year under contested circumstances step down and that by-elections be held. The plan also includes an inquiry into the deaths of 11 anti-government protesters earlier this month. Although the protestors are calling forKetasresignation, ECOWAS instead called for the rapid formation of a unity government that includes the opposition. However, theopposition coalition leading the protests, known as M5-RFP or the June 5 Movement, has rejectedthe proposed ECOWAS plan.

In Cte dIvoire,the rulingRally ofHouphoutistsfor Democracy and Peace (RHDP)has nominated current President Alassane Ouattara to run for president again after the recent death of the partys former nominee and current prime minister,AmadouGon Coulibaly.Notably,earlier this year Ouattarahad alreadydeclined to run for a third terminfavorof a successor.As of this writing,Ouattara has not yet accepted the nomination, but plans to give a speech on August 6 during which experts believe he will announce his decision. Notably, theopposition claims that Ouattara is not eligibleto run again.

Read more from the original source:

Africa in the news: New funding to fight COVID-19 in Africa, Somalias prime minister voted out, and political updates in Mali and Cte dIvoire -...

Sparano Shares Progress Made in the Molecular Guided Management of Breast Cancer – OncLive

The advent of gene expression assays has provided predictive insight into chemotherapy benefit that can be combined with prognostic information yielded by gene expression profiling to better target patients with breast cancer who are at higher clinical risk for the use of adjuvant chemotherapy, according to Joseph A. Sparano, MD.

The notion of precision medicine in breast cancer is not a new concept; it dates back to the 1970s when we began using ER and PR protein expression initially by ligand-binding assay and then by immunohistochemistry to identify patients who would benefit from adjuvant endocrine therapy, said Sparano, a professor of medicine and womens health at Albert Einstein College of Medicine, in a presentation during the 19th AnnualInternational Congress on the Future of Breast Cancer West, a virtual program by Physician Education Resource (PER).1

We then entered the second generation using gene amplification for HER2/neu via FISH testing to identify women who could benefit from adjuvant trastuzumab (Herceptin), an anti-HER2based therapy, added Sparano. Fifteen years into the third generation [we use] gene expression profiles to guide the use of adjuvant chemotherapy and endocrine therapy. We're currently pretty far into the fourth generation of assays in terms of mutational profiling, which can identify individuals who could benefit from targeted therapies.

In his presentation, Sparano, who is also an associate chairman in the Department of Oncology at Montefiore Medical Center, provided insight into advances made with gene expression profiles, the clinical utility of available assays, as well as future directions in this area.

Gene expression profiles first emerged in the breast cancer paradigm about 15 years ago based on unsupervised analyses, which indicated that breast cancer was a heterogenous disease, that there were distinct subtypes, and that prognosis could vary by subtype, according to Sparano. The unsupervised work resulted in the PAM50 assay (Prosigna), which can be used to identify the distinct breast cancer subtypes that exist.

The next generation of gene expression assays were based on supervised analyses, which evaluated genes associated with a better or worse prognosis. This research led to the development of various prognostic assays, which included the 21-Gene recurrence score assay (Oncotype DX) and the 70-Gene signature test (MammaPrint), among others.

One important point is that theres a lack of concordance in the prognostic classification provided by these assays, said Sparano.

Prospective Validation

The first trial to show that a gene expression assay could provide independent prognostic information was the B14 trial, which included archival samples from a total of 668 patients with estrogen receptor (ER)positive, node-negative breast cancer who had received treatment with tamoxifen for 5 years.

Fifty-one percent of patients fell into the low-risk group, which was defined as a recurrence score (RS) of less than 18, 22% of patients were in the intermediate-risk group (RS of 18-30), and 27% were in the high-risk group (RS of 31 or greater). The 10-year risk of distant recurrence was 7%, 14%, and 31%, respectively, for each of these groups.2

Further data revealed a statistically significant association for RS that was independent of age and tumor size, said Sparano. As such, RS was not a surrogate marker for these other factors; it provided independent prognostic information.

Results from another study, referred to as B20, went on to demonstrate prediction of benefit with these assays.3 A total of 651 patients with ER-positive, node-negative breast cancer were randomized to receive tamoxifen or tamoxifen plus chemotherapy. For the entire cohort you see approximately a 4% improvement in distant relapse-free survival for patients who received chemotherapy, noted Sparano. However, there was a very large benefit for patients who had a RS of 31 or higher; the absolute benefit was in the range of about 25% in the group with the highest RS, suggesting that one can identify, using this assay, a subpopulation of patients who are deriving all of the benefit from chemotherapy.

The prospective TAILORx trial included women with hormone receptorpositive, HER2-negative, and axillary node-negative breast cancer and they were randomized to treatment based on their RS.

Of the 10,273 women enrolled on the trial, 1629 who had a low RS of 0 to 10, were assigned to receive endocrine therapy alone (arm A). Women with a high RS of 26 to 100 were assigned to endocrine therapy plus chemotherapy (arm D). Those in the midrange who had a RS of 11 to 25 were randomized to receive either endocrine therapy plus chemotherapy in the standard arm (arm C), versus endocrine therapy alone in the experimental arm (arm B).

The study had a noninferiority design with invasive disease-free survival (iDFS) as the primary end point, and full information is expected after 835 iDFS events were reported.

We modified the mid-range group for several reasons. The TAILORx population excluded HER2-positive disease and we know that the 21-gene assay includes a HER2 module that drives the RS up and is associated with a higher score, but we know that most HER2-positive tumors have a higher RS, explained Sparano.5 As such, if you use the assay in a HER2-negative population, youll have a different RS distribution.

Additionally, the RS assay is used selectively in practice in situations where there is therapeutic equipoise, which is typically intermediate-grade tumors that are 1 cm to 2 cm; this results in more tumors having a score in the mid-range group, according to Sparano. The trial really needed to be designed to address that group, he said.

Moreover, the RS range was adjusted to preserve prediction in the highest-risk group and minimize the potential for undertreatment in the low-risk group, Sparano added.

Initial data from the low-risk group showed that at 5 years, the rate of freedom from recurrence of breast cancer at a distant site was 99.3% (95% CI, 98.7%-99.6%).4 This information was subsequently integrated into the American Joint Committee on Cancers Cancer Staging Manual, noted Sparano.

After a median of 7.5 years, results from the intent-to-treat population (arms B and C) were released and showed that the primary end point for iDFS was met (HR, 1.08; 95% CI, 0.94-1.24; P = .26), demonstrating noninferiority of endocrine therapy compared with the standard.6 Endocrine therapy alone was also found to be noninferior to chemoendocrine therapy with regard to freedom of recurrence of breast cancer at a distant site (HR, 1.10; 95% CI, 0.85-1.41; P = .48).

Investigators then examined whether any patients with a mid-range score were still deriving benefit from the chemotherapy. No benefit was observed with regard to increasing tumor size or grade, but statistically significant chemotherapy treatment interactions were observed between age, RS, and chemotherapy benefit. Patients who had a higher RS and a higher clinical risk within this younger group seemed to derive benefit, explained Sparano.

At 9 years, in those with a RS of 16-20, a 1.6% absolute benefit from chemotherapy was observed versus a 6.5% absolute benefit in those with RS ranging from 21 to 25, added Sparano.

An exploratory analysis looking at the impact of age and menopausal status on chemotherapy benefit in patients with a RS ranging from 16 to 25 showed that there was no benefit in older women with an increasing score. However, curves began to separate for younger women with a RS of less than 25, noted Sparano.

When examining absolute differences in 9-year distant recurrence rates by chemotherapy use in women 50 years or younger with RS of 16 to 25 stratified by RS and clinical risk, investigators noted that the estimated absolute benefit of chemotherapy in women with a RS of 16 to 20 who were not stratified by clinical risk was +1.6%. The estimated absolute chemotherapy benefit stratified by clinical risk was -0.2% in those with low clinical risk (n = 671) and a RS between 16 and 20 and +6.5% in those with high clinical risk (n = 215).7

When looking at the impact of age on chemotherapy benefit, investigators observed that women who were closer to menopause, aged 46 to 50 years, experienced the greatest benefit. Interestingly, younger women really had no benefit, suggesting that some of the effect that was seen with chemotherapy in these younger patients who had higher RS might have been due to a castration effect, explained Sparano.

At 9 years, a 3% distant recurrence with endocrine therapy alone was observed in patients with an RS of 0 to 10 (arm A). An overall 5% distant recurrence rate was reported in those with an RS between 11 and 25 (arms B and C). Between arms B and C, a less than 1% difference was observed for all end points. In those with a RS between 26 and 100 (Arm D), a 13% distant recurrence was observed, despite chemotherapy plus endocrine treatment.

MINDACT

The MINDACT trial included 6,693 patients who were assigned to a clinical risk or a genomic risk. Patients who had discordance in their clinical and genomic risks were randomized to receive either no chemotherapy or chemotherapy.8 The primary end point of the trial was distant metastasis-free survival at 5 years for those with high clinical risk and low genomic risk without chemotherapy.

No effect with chemotherapy was observed in older women, but there was a 5% benefit from chemotherapy in younger women, which is very similar to what we saw in TAILORx, said Sparano.

The phase 3 Plan B trial used the Oncotype DX Recurrence Score to define a genomically low-risk subset of patients with clinically high-risk pN0-1 early breast cancer for adjuvant treatment with endocrine therapy alone. A total of 3198 patients were enrolled on the trial and chemotherapy was omitted in 86.1% of eligible patients with a RS of 11 or less.

At a median follow-up of 5 years, DFS in the patients treated with endocrine therapy alone who had a RS of 11 of less was 94% versus 94% in those with an RS between 12 and 25 and 84% in those with an RS of greater than 25 (P < .001). In patients who received chemotherapy, the 5-year overall survival was 99% versus 97% versus 93%, respectively (P < .001).

This provided a limited amount of level 1 evidence supporting the use of the Oncotype assay in patients with low-volume disease, noted Sparano.

Future Directions

With all of the data yielded thus far, it is clear that gene expression assays provide prognostic information, that the 21-gene assay offers predictive information, and that the 70-gene assay provides prognostic information, according to Sparano.

Its important to remember that these assays are not interchangeable, and theres a lack of concordance in risk classification which needs to be considered when deciding which assay to use and what to do with the information yielded, concluded Sparano. Future plans involve integration of the clinical and gene expression profile information to recalibrate existing tools in an effort to provide more refined information regarding prognosis as well as an estimation of chemotherapy benefit.

Read more here:

Sparano Shares Progress Made in the Molecular Guided Management of Breast Cancer - OncLive

Stress-sensing Molecule May Be Potential Therapeutic Target in ALS – ALS News Today

A small molecule called microRNA-182-5p (miR1825p) is involved in the detection of cell stress and in the survival of motor neurons, the cells progressively lost in people inamyotrophic lateral sclerosis(ALS), a study in mice showed.

These findings shed light on the mechanisms behind ALS stress-associated nerve cell death and provide new potential therapeutic targets.

The study, MicroRNA1835p is stressinducible and protects neurons against cell death in amyotrophic lateral sclerosis, was published in the Journal of Cellular and Molecular Medicine.

MicroRNAs, or miRNAs, are small RNA molecules that target a specific genes messenger RNA (mRNA) the genetic blueprint derived from DNA and used as a template for protein production to prevent generation of that protein. A single miRNA can regulate several mRNAs.

Increasing evidence suggests that miRNAs dysregulation contributes to neurodegeneration in ALS patients, which may help toidentify new diagnostic biomarkers and develop new therapeutic approaches for ALS.

Notably, miRNAs were found to be involved in the detection and response to cell stressincluding oxidative stress, which promotes the toxic build-up of TDP-43 clumps, problems in mitochondria(the cells powerhouses), and nerve cell death in ALS.

Oxidative stress is an imbalance in the production of harmful molecules calledreactive oxygen speciesthat can lead to cell damage and death.

While problems in stress detection or response may contribute to nerve cell death in ALS, such underlying mechanisms remain largely unknown.

Researchers at West China Hospital of Sichuan University, in China, now have discovered that miR1825p, a microRNA known to be dysregulated in several cancers, is highly present in motor neurons nerve cells that control voluntary muscle movement and regulates stress-sensing mechanisms and cell death in a mouse model of ALS.

The team first found that while miR1825p was detected in several organs and tissues of healthy mice, its highest levels were present in the spinal cord, particularly in the region containing motor neurons.

The researchers then assessed whether miR1825p levels in the spinal cord were different between healthy mice and a mouse model of ALS.

Mice with ALS had significantly higher miR1825p levels in the pre-symptomatic and early symptomatic stages of the disease and significantly lower levels in the late stages, compared with healthy mice.

This drop in miR1825p levels in late ALS stages may be related to its characteristic, progressive loss of motor neurons, the researchers noted.

Database analyses identified a total of 399 potential genes targeted bymiR1825p, which were involved mainly in cell stress responses and cell death. Further tests in lab-grown mouse nerve cells, including motor neurons, showed that miR1825p was produced in response to several stress conditions associated with ALS.

These included oxidative stress, endoplasmic reticulum stress(a kind of stress response to defective protein production), andtumor necrosis factor (TNF) alpha, an inflammatory molecule.

Notably, blocking miR1825p in nerve cells under such stress conditions led to a drastic increase in cell death, while promoting higher-than-normal levels of miR1825p had a protective effect.

Further analysis revealed that miR1825p regulates nerve cell death by directly suppressing PDCD4 a critical protein in apoptosis, the natural process of programmed cell death and RIPK3 a wellknown regulator of necroptosis, a form of inflammatory cell death associated with motor neuron death in ALS.

These findings highlight that miR1835p is not only a stress sensor in motor neurons, but also an executive factor in neuron death programming, the researchers wrote, noting that it protects neurons against cell death under stress conditions.

Our study supplements current understanding of the mechanistic link between cell stress and death/survival, and provides novel targets for clinical interventions of ALS, the team wrote, adding that increasing the levels of miR1835p may potentially prevent motor neuron death in ALS.

Given that a previous study showed that white blood cells of Chinese ALS patients had significantly lower levels of miR1825p, compared with those of healthy people, miR1835p may have a systemic (body-wide) role in ALS, the researchers noted.

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

Total Posts: 0

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

Originally posted here:

Stress-sensing Molecule May Be Potential Therapeutic Target in ALS - ALS News Today

Electroceuticals/Bioelectric Medicine Market to Witness Tremendous Growth in Coming Years || Leading Players – BioElectronics Corporation, SetPoint…

Electroceuticals/Bioelectric Medicine Market

For in-depth understanding of market and competitive landscape, this Electroceuticals/Bioelectric Medicine Market research report provides a lot of parameters and detailed data about Healthcare industry. The report offers persistent knowledge and information of revolutionizing market landscape, what already exists in the market, future trends or what the market expects, the competitive environment, and strategies to plan to outshine the competitors. Various market related parameters considered in this Electroceuticals/Bioelectric Medicine Market research report helps businesses for better decision making.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-electroceuticalsbioelectric-medicine-market&rp

Market Analysis:Global Electroceuticals/Bioelectric Medicine Market

The electroceuticals/bioelectric medicine market accounted to USD 17.26 Billion in 2016 growing at a CAGR of 8.1% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Major Market Competitors:Global Electroceuticals/Bioelectric Medicine Market

Some of the major players operating inelectroceuticals/bioelectric medicine marketareMedtronic, Abbott, Boston Scientific Corporation, Cochlear Ltd., Livanova PLC, Sonova, BIOTRONIK SE & Co. KG, Nevro Corp., SECOND SIGHT, electroCore LLC, Synapse electroceutical Ltd., BioElectronics Corporation, SetPoint Medical, Inc., Bright Medical Ltd, GlaxoSmithKline Plc, EnteroMedics Inc., Alphabet Inc., The Medicines Company, FRV ELECTROCEUTICALS and Valencia Technologies Corporationamong others.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-electroceuticalsbioelectric-medicine-market&rp

Market Definition:Global Electroceuticals/Bioelectric Medicine Market

Bioelectric medicine combines bioengineering, molecular medicine, and neuroscience to develop nerve-stimulating technologies for the parameter of biological processes during treatment of disease. Increasingincidences of chronic diseases such as cardiac and neurological disorders leads to the market growth. Thus, there is high demand for advanced bioelectric medicine for the treatment of these chronic disorders.

Major market drivers and restraints:

Market Segmentation:Global Electroceuticals/Bioelectric Medicine Market

The electroceuticals/bioelectric medicine market is segmented by product into implantable cardioverter defibrillators, cardiac pacemakers, spinal cord stimulators, cochlear implants, deep brain stimulators, transcutaneous electrical nerve stimulators, vagus nerve stimulators, sacral nerve stimulators and retinal implants.

By type of device the market is segmented into implantable electroceutical devices and non-invasive electroceutical devices.

By application the market is further segmented into cardiac pacemakers and implantable cardioverter defibrillators market, spinal cord stimulators market, cochlear implants market, deep brain stimulators market, transcutaneous electrical nerve stimulators market, vagus nerve stimulators market, sacral nerve stimulators market, retinal implants market and others.

Cardiac pacemakers and implantable cardioverter defibrillators marketis sub segmented by application into arrhythmia.Spinal cord stimulators (SCS) market is sub segmented by application into chronic pain, failed back syndrome (FBSS) and ischemia.Cochlear implants market is sub segmented by application into sensorineural hearing loss.Deep brain stimulators (DBS) market is sub segmented by application into Parkinsons disease, tremor, depression and other. Transcutaneous electrical nerve stimulators (TENS) market is sub segmented by application into treatment-resistant depression and other.Vagusnerve stimulators market is sub segmented by application into epilepsy and other.Sacral nerve stimulators (SNS) market is sub segmented by application into urinary incontinence and fecal incontinence.Retinalimplants market is sub segmented by application into retinitis pigmentosa.Other market is sub segmented by application into gastroparesis obesity, depression, migraine and spinal cord injury.

By end user the market is segmented into hospitals, clinics, research institutes and individual users.

On the basis of geography, electroceuticals/bioelectric medicine market report covers data points for 28 countries across multiple geographies such as North America & South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, andBrazil among others. In 2017, North America is expected to dominate the market.

Competitive Analysis:Global Electroceuticals/Bioelectric Medicine Market

The electroceuticals/bioelectric medicine market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of electroceuticals/bioelectric medicine market for global, Europe, North America, Asia Pacific and South America.

Research Methodology:Global Electroceuticals/Bioelectric Medicine Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more pleaseRequest an analyst callor drop down your enquiry.

Demand Side Primary Contributors: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-electroceuticalsbioelectric-medicine-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Read more from the original source:

Electroceuticals/Bioelectric Medicine Market to Witness Tremendous Growth in Coming Years || Leading Players - BioElectronics Corporation, SetPoint...

Digong forgot to mention the cure for Covid-19 The Manila Times – The Manila Times

ONE of the highlights in President Rodrigo Digong Dutertes fifth State of the Nation Address (SONA) was his proposal to Congress to revive the death penalty through lethal injection.

The death penalty law was passed during the term of President Fidel Ramos, but was scrapped by President Gloria Macapagal Arroyo, who gave in to pressure from the Catholic Church.

The death penalty could decrease the commission of heinous crimes.

Digong said drug offenses would be covered by his proposed death penalty.

But how about rape with homicide, rape of a minor, murder, robbery with homicide and large-scale estafa?

How about law enforcers who commit grave offenses using their badges as a shield? Among the serious crimes by law enforcers is planting evidence on innocent citizens.

How about government officials who coddle big-time criminals?

The above-cited offenses should have been included by Digong as punishable by lethal injection.

If Congress considers the Presidents proposal to restore the death penalty, it should include the other heinous crimes mentioned above.

* * *

Congress should not listen to bleeding hearts like Amnesty International since they refuse to see the real crime situation in the Philippines.

Bleeding hearts were not able to stop the death penalty in many countries, including some states in the United States.

Why should they stop our country from restoring the death penalty?

* * *

I was expecting the President to announce the discovery by Filipino doctors of a cure for seriously ill coronavirus disease 2019 (Covid-19) patients in the SONA.

The citizenry, cowering in fear of the dreaded illness, would have appreciated the Presidents speech more if he had included the medical breakthrough.

The medical breakthrough was announced by Palace spokesman Harry Roque Jr. in a virtual press conference in Malacaang several days before the SONA.

However, the story was buried in the inside pages of major newspapers, a treatment it did not deserve.

The discovery of the cure for Covid-19 was made by scientists at The Medical City hospital through its Institute of Molecular Medicine stem cell program.

Stem cells taken from the blood of preserved umbilical cords worked their magic on six patients about to be intubated through intravenous injections.

I wrote about the medical breakthrough in my column last Tuesday, July 28.

For those who missed that column, you may want to read it at the Manilatimes.net.

* * *

A big supply of umbilical cords would bring down the cost of the stem cell therapy for Covid-19.

Tens of thousands of women give birth in the country and the umbilical cords of the newborns are thrown away.

The possible sources of umbilical cords are government hospitals and paanakan (maternity) centers.

The Philippines is a big manufacturer of babies.

Proof is that for a small country, our population has ballooned to 110 million.

To digress, I was a medical representative (detailman) in 1973 and one of the hospitals in Metro Manila that I was assigned to cover was the Fabella Memorial Hospital, a maternity hospital, in Sta. Cruz, Manila.

As I was fixing the promotional medicines I would give to some doctors at Fabella, I heard the screams of pain by a woman about to give birth at the delivery room.

Armando, Armando! P****g i*a mo! the woman was shouting, apparently referring to her husband.

I heard the nurse or midwife tell the woman, Tumigil ka nga diyan! Huwag mong sisihin ang asawa mo. Taun-taon nandito ka (Shut up! Dont blame your husband. Youre here every year).

See what I mean by the country being a manufacturing center of babies?

* * *

Another highlight of the Presidents SONA was his plan to establish the Coconut Farmers Trust Fund.

That part of Digongs speech was near to my heart as I come from Davao Oriental, a province where the main livelihood of the people is harvesting coconuts and turning them into copra.

Coconut farmers are the poorest in the country.

It was not so before, say, in the 1960s, when the price of copra was very high and coconut farmers in my hometown Manay could send their children to very good schools in Davao City and elsewhere.

But the price of copra in the world market is now very low and Filipino coconut farmers have become impoverished as a result.

However, the dying coconut industry might soon come to life again and the farmers could be rich once more.

An American friend of mine, Matt Grecsec, has invented a machine that converts coconut husk into hardwood for construction materials.

Grecsec, whos from Florida and married to a Filipina, has been coming to the Philippines looking for a place to set up his plant to make hardwood out of coconut husk.

Coconut husk is thrown away by farmers who make copra.

Grecsec has been meeting with Agriculture Secretary William Dar who has expressed enthusiasm for his project.

Go here to see the original:

Digong forgot to mention the cure for Covid-19 The Manila Times - The Manila Times

Coronavirus testing hits a wall: Where do we go from here? – MedTech Dive

This story is part of a MedTech Dive series examining the impact of the COVID-19 pandemic on the medtech industry, published six months after the U.S. declared a public health emergency. You can find the other stories here.

When the U.S. declared a public health emergency on the final day of January in response to the coronavirus pandemic, it was clear the nation lacked the diagnostic capabilities to combat the rapidly spreading infection.

Six months later, COVID-19 cases are surging in the South and West. But despite new tests coming online from companies such as Abbott, BD, Roche and Thermo Fisher and a capacity ramp-up by commercial labs like LabCorp and Quest, the nation is still only able to muster 4.5 million tests per week.

Thats a far cry from the 30 million tests weekly needed within the next three months to safely reopen communities and state economies, and keep them open, according to the Rockefeller Foundation, which this month proposed a National COVID-19 Testing & Tracing Action Planto address the shortfall.

Echoing many other public health experts, the plans authors warn the U.S. is losing its battle against COVID-19 and that testing is the only way to avert further devastation until a vaccine or effective therapeutics are widely available.

The Rockefeller authors contend that within the next three months to contain the pandemic, what's required is access to diagnostic testing for Americans with symptoms at least 5 million tests per week with turnaround times of less than 48 hours as well as 25 million fast, inexpensive screening tests for asymptomatic people.

The national focus should not just be on bringing more COVID-19 diagnostic tests to the market, but significantly boosting onsite and home testing of people not showing symptoms,the foundation contends.

Abbott Labs, whose point-of-care ID Now platform was one of the first molecular tests to get an FDA emergency use OK,is also betting that large scale rapid testing is the next chapter of the pandemic response.

With the phased easing of shelter-in-place restrictions, were entering a new phase where continued testing of symptomatic patients will start to overlap with broader surveillance testing of asymptomatic patients in order to better track, understand and contain the spread of the virus until we have broad vaccine availability, Abbott CEO Robert Ford told investors on a July 16 second-quarter earnings call.

While the FDA has cleared more than 150 molecular tests, only two antigen tests, sold by BD and Quidel, have emergency use authorization.Abbott is now working on its own antigen test.

Unlike polymerase chain reaction tests, which detect viral genetic material, antigen testing is designed to determine if a sample contains proteins found on the surface of the coronavirus, enabling delivery of results in minutes rather than days.

Some public health experts are advocating a broad push using the antigen tests, especially as LabCorpand Quest struggle to keep up with increased demand for molecular diagnostics as U.S. coronavirus cases rise.

Whereas molecular tests are typically highly accurate and usually do not need to be repeated, FDA has recommended that negative results from antigen tests should be confirmed with a molecular test. In particular, the agency has warned that antigen tests are not able to definitively rule out active COVID-19 infection.

"Thats why when the FDA approved those assays, they approved it under the remark that if its negative you have to reconfirm it with a PCR assay. And obviously most are negative, so you have to do a lot of PCR assays following that,"Roche Diagnostics CEO Thomas Schinecker told investors on a Thursday earnings call.

However, Mara Aspinall, a biomedical diagnostics professor at Arizona State Universitys College of Health Solutions, makes the case that the U.S. cannot break the chain of transmission if the coronavirus outpaces public health efforts.

Whats needed is a paradigm shift from exquisitely accurate-but-slow tests to fast-and-good enough to quarantine," she said.Slow and accurate works for clinical management, but this virus is a sprinter not a marathoner.We need fast and frequent tests just to keep up."

That approach has been endorsed by top U.S. health officials, including National Institutes of Health Director Francis Collins and federal testing czar Brett Giroir.

Earlier this month, FDA granted emergency use authorization to BDs rapid, point-of-care coronavirus antigen test, making it only the second such diagnostic to receive a nod from the regulatory agency.

A Quidel product, which claimed the antigen category's first EUAin May, delivers results in 15 minutes.BD's test, which runs on the company's widely used Veritor Plus System, also delivers results in 15 minutes.

What appears to set Quidel's antigen-based diagnostic apart from BD's is its accuracy. Quidel on July 17 sharednew data showing its COVID-19 antigen test has 96.7%sensitivity which is comparable to the sensitivity rates of PCR tests, according to the company.

"Lower sensitivity had been an argument we have heard over and over about why antigen testing was not going to be used and this should help put that to bed," William Blair analysts wrote in a July 20 note to investors.

The analysts contend Quidel's latest data on its antigen test puts it "on par with many of the molecular tests on the market" as well as "above the performance of the other antigen test on the market from BD."

By comparison, BD's antigen test has 84% sensitivity. Asked if BD is looking to update its clinical performance data, a spokesperson told MedTech Dive they are not aware of any plans to do so.

As for Abbott,CEO Ford declined during the July 16 earnings call to provide specifics in terms of timing and when the diagnostic might be available. He did say antigen tests offer an interesting value proposition compared to molecular testing.Ford emphasized that Abbotts goal is to produce a reliable antigen test thats easy to use and, equally important, is affordable.

I think thats the critical aspect here. If we want to get to more mass screening, more mass volume, these tests need to be more affordable, and one of the ways you do that is you remove the restriction on the [lab-based] instrument, or requiring an instrument, he told investors.

When it comes to diagnostic testing, easy, fast, and cheap is also what the Rockefeller Foundation is advocating to bring tests to the U.S. market at a national scale needed to effectively respond to the pandemic. The organization envisions point-of-careantigen tests costing $5 to $10 per test, with same-day test results for schools and workplaces, and even faster turnaround times for mobile testing in communities.

Today the country conducts almost zero such [screening] tests, and we need at least 25 million per week for schools, health facilities, and essential workers to function safely, wrote Rajiv Shah, president of the Rockefeller Foundation, in the organizations proposed national testing plan.

The U.S. will need at least another $75 billion in federal funding for testing to reach the plans goal of 30 million tests per week by October, including at least 25 million fast, inexpensive antigen tests for asymptomatic Americans, according to the Rockefeller Foundation.

The call for more money for testing comes as a debate continues on Capitol Hill over what the next coronavirus relief bill should appropriate.The HEROES Act passed by House Democrats in May providesan additional $75 billion for testing but Senate Republicans are likely to come up with their own legislation with less funding.

Senate Republicans are considering much lower figures for testing as President Donald Trump has resisted more testing on a false claim that it leads to more cases.

The Rockefeller Foundation also wants the administration to invoke the Defense Production Act, or similar federal program, to jumpstart producing and distributing mass quantities of fast, low-cost antigen tests. The administration reluctantly used the Korean War-era law earlier in the pandemic to force industry's hand in producing ventilators.

Fueled by soaring demand for molecular diagnostic testing across the country,particularly in the South, Southwest and West, current test processing delays experienced by the two largest commercial labs are hamstringing Americas COVID-19 response.

Quest reportedJuly 20 that non-priority patients face average wait times for their test results of seven or more days, while "priority 1" patients, or those considered critical, are now having to wait an average of more than two days for results. A company spokesperson told MedTech Dive the company is "planning to issue updated numbers" on Monday afternoon."Otherwise, the July numbers are the most up to date," she said.

By comparison, LabCorp reported Sunday its average wait time for results was two to three days from specimen pickup, down from three to five days last week, and that turnaround times are "faster" for hospitalized patients.

Nonetheless, slower than 48-hour turnaround times for test results are making contact tracing ineffective. In fact, a studypublished on July 16 in The Lancet found that test results need to be delivered within a day of a person developing symptoms for contact tracing to be effective in reducing transmission of the coronavirus.

As LabCorp and Quest are having a hard time meeting hotspot-driven demand in a timely fashion,the Trump administration is hoping rapid point-of-care tests from Abbott, BD and Quidel can alleviate the pressure.

Giroir, lead for federal COVID-19 testing efforts, has touted the ability of antigen-based tests from BD and Quidel, as well as Abbott's ID Now molecular test, to be performed outside of lab settings in minutes rather than days.

The testing czar acknowledged Sunday that test results are taking too long. "The delays that most people talk about are at the large commercial labs that perform about half the testing in the country,"Giroir said on CNNs State of the Union, while estimating that the average turnaround is about 4.27 days."I would be happy with point-of-care testing everywhere. We are not there yet,"he added.

NIH director Collins has echoed those sentiments, commenting that wait times for test results are "too long" currently and rapid antigen-based diagnostics could be the answer.

Writing in a New England Journal of Medicine article published Wednesday, Collins and his co-authors noted that while PCR tests are highly sensitive they require a large amount of lab space, complex equipment, regulatory approvals for lab operations, as well as skilled technicians to run them.In addition, they said with this type of testing there is the need to transport specimens to a central lab that leads to further delays.

"For this reason, low-complexity molecular diagnostic point-of-care tests with rapid turnaround have substantial practical advantages," wrote Collins and others, who pointed out that antigen testing can provide quick results "similar to the way pregnancy tests operate." They noted that a number of manufacturers are currently developing them.

A Quest spokesperson told MedTech Dive that "there remains value in molecular diagnostic testing." At the same time, they said the company is "exploring the option to launch its own antigen test" but declined to disclose any additional details. LabCorp currently has no plans for antigen testing, according to a company spokesperson.

Quest's future plans for an antigen test aside, the company is taking other approaches to molecular testing in an attempt to maximize capacity.On July 18 it announced its PCR test, which first got emergency use authorization by FDA in March, was granted an agency EUA for sample pooling, a method meant to screen more people using fewer testing resources.

LabCorp announcedSaturday that it also received an EUA from FDA authorizing diagnostic testing of groups of individuals for active COVID-19 infections using pooled testing.

Sample pooling, in the case of Quest's molecular test, allows specimens collected from four individuals to be tested in a pool or batch using one test, rather than running each in its own test. LabCorp's pooled testing method involves testing up to five samples at once.

Quest acknowledges the inherent limitation of sample pooling:it's only an efficient way to evaluate patients in regions or populations with low rates of disease. Quest Chief Medical Officer Jay Wohlgemuth said in a statement that while sample pooling will help expand testing capacity it is not a "magic bullet" and "testing times will continue to be strained as long as soaring COVID-19 test demand outpaces capacity."

While LabCorp believes pooled testing can increase its overall testing capacity, the company concedes that specimens with low viral loads may not be detected in sample pools due to decreased sensitivity and that the method may be used for populations at low risk, when testing demand exceeds capacity, or when reagents are in short supply.

However, the Rockefeller Foundation argues that despite testing advancements such as sample pooling,the commercial labs cannot come close to fulfilling the nations screening test needs.

Lab tests arent convenient, simple, or inexpensive enough to use at the scale needed, the report says,calling for a ramp-up in antigen testing in schools, offices and beyond.

The Rockefeller Foundation also believes it is critical for the U.S. to look beyond commercial laboratories such as LabCorp and Quest that are overwhelmed and tap the testing resources of other underutilized labs, recruiting academic and other labs.

However, time is of the essence, according to Shah."We will soon enter a new cold and flu season with potentially 100 million cases of flu-like symptoms that stand to overwhelm our current testing capacity."

Visit link:

Coronavirus testing hits a wall: Where do we go from here? - MedTech Dive

Study Suggests New Approach to Improve Radiation Therapy Resistance in Glioblastoma – Michigan Medicine

The group found that the cell lines that were more resistant to radiation treatment also had higher levels of purines biological compounds that are known as the building blocks of DNA and RNA, and that can also activate signaling pathways.

This was very exciting because lots of different genetic mutations that occur in glioblastoma lead to this purine pathway being activated, Wahl says.

This suggested that they might be able to target the downstream effect of multiple genetic mutations.

We hypothesized that targeting this metabolic activity might work across tumor cells with different types of mutations instead of just whatever fraction of cells has that one particular genetic aberration you might go after with a mutation-targeting therapy.

Once the researchers discovered the correlation between high levels of purines and radiation resistance, they set out to demonstrate whether the metabolic changes actually caused the radiation to be less effective.

We gave cells more purines. It made them more resistant, Wahl says. We took away purines. It made them more sensitive to radiation. And we found it was doing this by affecting the cells ability to repair radiation-induced DNA damage.

To better understand whether targeting purine metabolism might help overcome resistance to radiation therapy in patients, the team used mouse models of glioblastoma with tumors grown from human patients cells.

They gave the mice a drug called mycophenolate mofetil, or MMF, which blocks purine biosynthesis and which has been approved for the treatment of organ transplant rejection since 2000.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

Tumor growth was moderately slowed down in mice who received radiation therapy alone or MMF alone, but almost totally halted in the mice who received both, Wahl explains. The benefits of MMF were similar whether animal tumors were grown in the brains of the mice or elsewhere in their bodies, demonstrating the drugs ability to effectively penetrate the blood-brain barrier which is critical for treating brain cancer patients.

Since the FDA has already found the drug to be safe enough to use in patients for one purpose, it makes it easier to set up a clinical trial aimed at a second disease, he says.

Ultimately, Wahl adds, the research was made possible by the collaborative, multidisciplinary environment at U-M where clinicians and researchers with expertise in glioblastoma can team up with others who specialize in cancer metabolism, data modeling and launching new clinical trials.

None of this happens without all these different teams sharing knowledge, models, methods and enthusiasm for making a difference in the lives of patients, he says.

Additional authors include Weihua Zhou, Andrew J. Scott, Kari Wilder-Romans,Joseph J. Dresser, Christian K. Werner, Hanshi Sun, Drew Pratt, Peter Sajjakulnukit, Shuang G. Zhao, Mary Davis, Meredith A. Morgan, Alnawaz Rehemtualla, Barbara S. Nelson, Christopher J. Halbrook, Li Zhang, Angela K. Walker, Maureen Kachman, Jianping Xiong, Maria G. Castro, Pedro Lowenstein, Sriram Chandrasekaran, Theodore S. Lawrence and Costas A. Lyssiotis of U-M; Yangyang Yao of U-M and First Affiliated Hospital of Nanchang University, China; Francesco Gatto of Chalmers University of Technology, Gteborg, Sweden; and Jann N. Sarkaria of the Mayo Clinic.

The research was supported by grants from the American Cancer Society, the Forbes Institute for Cancer Discovery, the National Cancer Institute (K08CA234416), the Jones Family Foundation Fund within the Chad Carr Pediatric Brain Tumor Center and U-M Taubman Emerging Scholars Program, as well as grants from the National Institutes of Health, the Michigan Institute for Clinical & Health Research, Rogel Cancer Center, an AACR NextGen Grant for Transformative Cancer Research (17-747 20-01-LYSS) and an American Cancer Society Research Scholar Grant (RSG-18-186-01).

Paper cited: Purine metabolism regulates DNA repair and therapy resistance in glioblastoma, Nature Communications. DOI: 10.1038/s41467-020-17512-x

Follow this link:

Study Suggests New Approach to Improve Radiation Therapy Resistance in Glioblastoma - Michigan Medicine

Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis – BioSpace

DURHAM, N.C., July 29, 2020 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced that it has acquired exclusive rights to a gene therapy targeting GUCY2D-associated Leber congenital amaurosis (LCA1), a genetic eye disease that affects the retina and is a leading cause of blindness in children, from Sanofi, which originally licensed it from the University of Florida. The therapy was created in the laboratory of Atsena Founder and Chief Scientific Officer Shannon Boye, Ph.D., and Founder and Chief Technology Officer Sanford Boye, M.Sc., at the University of Florida.

We are thrilled that our gene therapy for LCA1 is coming home to Atsena and that we will have the opportunity to further its development, said Shannon Boye. Atsena was founded to advance treatments for inherited retinal diseases and believes in centering patients perspectives and needs in all we do. We are honored to continue to work with LCA1 patients and their families as we strive to treat this debilitating disease.

LCA is the most common cause of blindness in children, impacting two to three per 100,000. LCA1 is caused by mutations in the GUCY2D gene and results in early and severe vision impairment or blindness. GUCY2D-LCA1 is one of the most common forms of LCA, affecting roughly 20 percent of patients who live with this inherited retinal disease.

Atsena has an ongoing Phase I/II clinical trial evaluating this gene therapy in LCA1 patients. The second cohort in the trial is expected to be dosed in the fall of 2020.

Atsenas gene therapy has the potential to be a major advance in treating blindness in both children and adults affected by this inherited retinal disease, said Benjamin Yerxa, Ph.D., Chief Executive Officer of the Foundation Fighting Blindness and Atsena board director. The foundation was instrumental in supporting proof of concept studies in the founders labs over the last 15 years. Now, via investment in Atsena through our Retinal Degeneration (RD) Fund, we are excited to support this potential breakthrough treatment for LCA1.

Atsena closed a Series 1 funding of $8.15 million in April 2020, led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness RD Fund with participation by Osage University Partners, PBM Capital and the University of Florida. Patrick Ritschel, M.B.A., co-founder and former President of gene therapy company StrideBio, serves as Atsenas Chief Executive Officer.

Atsena is pleased to have the support of an enthusiastic investor base that shares our dedication to bringing the life-changing power of genetic medicine to patients living with LCA1 and other forms of blindness, said Ritschel. We look forward to working closely with our investors and patients as we continue to grow, and expect to announce additional milestones later this year.

About Atsena Therapeutics

Atsena Therapeutics is a clinical-stage gene therapy company, focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. The company has an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Its additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome the hurdles presented by inherited retinal disease, and its approach is guided by the specific needs of each patient condition. Founded by pioneers in ocular gene therapy, Atsena has a licensing, research and manufacturing collaboration with the University of Florida and is headquartered in North Carolinas Research Triangle, an environment rich in gene therapy expertise. For more information, please visit atsenatx.com.

Media Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com

More here:

Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis - BioSpace

Our Genes May Explain Severity of COVID-19 and Other Infections – Quanta Magazine

Why was a marathon runner in his 40s stricken with a case of COVID-19 so severe it landed him in the intensive care unit? Why did a healthy 12-year-old boy lose his life to a disease that mostly harms older people? One of the most terrifying aspects of the pandemic is that the severity of the disease seems so cruelly and arbitrarily variable.

Although the SARS-CoV-2 virus is most often fatal in patients who are elderly or have chronic medical conditions such as diabetes, heart disease or high blood pressure, exceptions that bring down apparently healthy young people are commonplace. Even patients who do not die of the infection show a huge spread in their symptoms: Some never get sick; some need to be hospitalized but recover; some have lingering disabilities that last for months.

So far, scientists have been largely at a loss to explain why COVID-19 hits patients as hard as it does, though reasons surely exist. Its not just bad luck, said Helen Su, an immunologist at the National Institute of Allergy and Infectious Diseases.

One possibility under investigation is that some people harbor genes that put them at greater or lesser risk from COVID-19. The COVID Human Genetic Effort, for example, is enrolling hundreds of patients from around the globe who wound up in intensive care after infection with the SARS-CoV-2 virus. Initially, the project only enrolled patients who were under age 50 and had no underlying health conditions, though it has more recently expanded eligibility.

My hope is to understand the genetic basis of severe COVID in patients of all ages and regardless of comorbidities, said Jean-Laurent Casanova, a researcher in pediatric medicine and immunology at the Rockefeller University who co-founded the project with Su and others. And from that, to understand the mechanism that makes them vulnerable to SARS-CoV-2.

Some genetic clues may already be coming to light. Last week, a team of researchers in the Netherlands published a preliminary communication online in JAMA about four young male patients from two families who all suffered severe COVID-19 respiratory illnesses. The men, who were between the ages of 21 and 32, had no history of chronic medical problems, but DNA sequencing revealed that each of them had a rare form of a gene on his X chromosome that was linked to a deficient immune response. Much more study will be needed to determine whether similar deficiencies, possibly involving other genes, are common among COVID-19s worst cases.But in a study appearing in Nature today, researchers at the Yale University School of Medicine who followed the progression of COVID-19 in 113 hospitalized patients for two months found that greater severity of the disease was associated with maladaptive immune responses. (The causes for those immunological misfires was not determined.)

The significance of these discoveries may not be limited to COVID-19. Casanova is a champion for an idea that has been slowly gaining credence among medical researchers for many years: that genetics is always a factor in infectious diseases. Many if not all people may have very specific genetic vulnerabilities, such as weaknesses in their immune system, that go unnoticed until one particular pathogen crosses their path. That genetic trait is their Achilles heel, and that pathogen is the one thing that can take advantage of it.

The theory has emerged out of both clinical practice and scientists growing appreciation of the interconnection between genes and infectious diseases. Casanova has spent the past 25 years scanning the genomes of young people who were inexplicably debilitated by commonplace pathogens like the herpes simplex and varicella zoster viruses (which cause cold sores and chickenpox, respectively). In these children, who showed no outward symptoms of compromised immunity, he has found defects in genes that make them susceptible to severe infection with a single pathogen. In most cases, there were no clinical signs of a genetic problem until they were infected.

For many of these immune deficiencies where children or adults have very severe infections there is a genetic basis, said Trine Mogensen, a physician at Aarhus University and a member of the COVID Human Genetic Effort steering committee.

If the COVID project succeeds in finding genes relevant to the course of the infection, it could fuel interest in widening that search for other conditions. Further work on the interplay of infections, immunity and genomes could change how future gene-based medicine routinely diagnoses and treats diseases.

Infectious disease has always been one of greatest threats to humanity. Before the invention of antibiotics, infections killed half of all children by age 15. Yet as terrible as their collective toll has been, even the worst infectious diseases kill relatively few of those they infect. Tuberculosis has been a scourge, but fewer than 10% of people infected with it even get sick. Even the terrible Spanish flu pandemic that started in 1918 had a mortality rate often estimated at around 2.5%.

Variability in disease severity is usually chalked up to circumstantial factors: the virulence of different pathogen strains, the amount of pathogen exposure, the nutrition or general health of a patient. Researchers have suspected, however, that something more is lurking in the genes of the hardest-hit patients.

The idea of a genetic component to infection dates back to 1905, when an English scientist named Rowland Biffen discovered a gene responsible for a devastating fungal disease called yellow rust that was killing wheat and diminishing crop yields across England. He found that resistance to the fungus was present in some of the plants as a recessive trait passed down from parent to offspring without affecting other characteristics of the plant. The discovery was celebrated, and his method of breeding for resistant plants is still widely used today.

These types of genes were later found in other plants and animals. But genetic immunodeficiencies in humans didnt start to attract attention until the 1950s, when an immune disorder was identified in an 8-year-old boy being treated at Walter Reed Army Medical Center for recurrent blood infections. The disorder, known as X-linked agammaglobulinemia, inhibits the bodys ability to make the antibodies called gamma globulins, resulting in severe infections even from fairly innocuous pathogens.

The boy had suffered 19 bouts of pneumococcal meningitis, which were repeatedly treated with antibiotics. His condition improved more lastingly only after his physician, Ogden Bruton, discovered that the boy had almost no gamma globulins in his blood. Bruton promptly began treating him with monthly injections of gamma globulins, and the boy survived to adulthood. The discovery, which was described in Pediatrics in 1952, was later recognized as a milestone, highlighting the role of defects of the immune system in inhibiting the fight against infection. These defects were later termed inborn errors of immunity.

Read more:

Our Genes May Explain Severity of COVID-19 and Other Infections - Quanta Magazine

Omega Therapeutics Lands $85M to Tap Into Control Room of Biology – Xconomy

XconomyBoston

The promise of gene therapies and gene-editing drugs is a long-lasting treatment thats potentially a cure. But making permanent genetic changes means any accompanying problems could be long-lasting as well, says Omega Therapeutics CEO Mahesh Karande.

Omega is developing technology that takes a more nuanced approach to genomic medicine. Instead of fixing or replacing faulty genes, the company aims to harness the biological system that regulates them. If a gene is not properly translating DNA instructions into a needed protein, Omega can tune the gene expression up, Karande says. If gene expression is too high, the companys technology dials it down.

We have basically tapped into the control room of biology, says Karande, a former executive at Macrolide Pharmaceuticals and Novartis (NYSE: NVS). Our therapeutics are allowing genes to express at their native, correct level of expression. We tap into that biology.

Now the Cambridge, MA-based biotech has tapped into something more: $85 million in financing. Karande says the cash will support multiple programs, the first of which is expected to reach clinical testing in 2021.

The system that regulates genes is called the epigenome. The targets of Omegas drugs are insulated genomic domains (IGDs), three-dimensional structures that rise up from the folds of DNA. IGDs regulate the activity of a gene, similar to the way a thermostat regulates the temperature of a room, the company says. Omega has developed technology that identifies IDGs and their biological functions in states of both health and disease.

Omegas drugs are fusion proteins made up of a delivery system that takes the therapy to specific cell types, a targeting domain that binds to a specific site on the IGD, and a functional domain engineered to tweak the activity level of the IGD as needed. A single Omega drug can control the gene expression of a single gene or multiple genes, Karande says. The company can also control the length of time that a drug works, making it last days, weeks, or longer. That makes the treatment applicable for acute conditions of short duration. And unlike the permanent change made by genomic medicines, if an epigenomic Omega therapy is no longer needed, it can be turned off.

Most gene therapies and gene-editing drugs are delivered by engineered viruses. In addition to hitting the intended genetic target, these viruses can also hit other places, causing side effects, says Tom McCauley, Omegas chief scientific officer. Also, gene-editing drugs use cutting enzymes that can snip unintended spots along the genome, sparking off-target effects. By contrast, Omegas targeted approach gives its drugs the potential to more safely treat genomic disorders with a degree of control not offered by gene therapies or gene-editing drugs, McCauley says.

There are other epigenetic medicines companies. Cambridge, MA-based Epizyme (NASDAQ: EPZM) is developing drugs addressing the genetic causes of disease. In January, the FDA approved the companys small molecule drug tazemetostat (Tazverik) as a treatment for the rare cancer epithelioid sarcoma. In June, it won an an additional nod for follicular lymphoma. The most advanced drug candidate, developed by another Cambridge-based epigenetics biotech, Constellation Pharmaceuticals (NASDAQ: CNST), is a small molecule in mid-stage testing in myelofibrosis, a rare blood cancer.

Theres a reason that most of the epigenetic medicines currently available and in drug pipelines are small molecules addressing some form of cancer, McCauley says. Those drugs do hit their cancer targets but they also go elsewhere in the body, sparking side effects, he says. That risk is acceptable in rare cancers, but untenable for other diseases. Cancer is one of Omegas disease targets, but McCauley says that Omegas capability to modulate the epigenome could more safely and effectively address other diseases as well.

The IDG science that is the basis for Omegas epigenomic approach stems from the research of Richard Young and Rudolf Jaenisch, MIT biology professors and members of the Whitehead Institute for Biomedical Research. In 2016, their research was published in the journal Cell. They are both scientific advisors to Omega, which was founded in 2017 by venture capital firm Flagship Pioneering, the companys only disclosed financial backer. The firm has a track record of starting companies, incubating them, and then spinning them out to advance their research.

Omega emerged from stealth last September. Karande would not say much about the companys disease targets then, and hes saying only a little more now. Without naming specific conditions, Karande says his startup aims to treat inflammatory and immunological disorders, metabolic conditions, and rare diseases where a targeted approach to modulating the epigenome enables the company to hit disease targets previously considered undruggable. The company currently has five programs. Karande says the new financing is enough to support all five, though he leaves open the possibility that some of them could be advanced in partnership with a large pharmaceutical company.

Were on a journey right now to get five programs, in a staggered fashion, into the clinic, he says. As we make milestones in the next few months, we will be talking about them.

Image: iStock/artisteer

Frank Vinluan is an Xconomy editor based in Research Triangle Park. You can reach him at fvinluan@xconomy.com.

Read the original:

Omega Therapeutics Lands $85M to Tap Into Control Room of Biology - Xconomy

EarlyBird Study: Early Detection of Adult-Onset Type 2 Diabetes in Youth – Diabetes In Control

Editor: David L. Joffe, BSPharm, CDE, FACA

Author: ChardaeWhitner, 2020 PharmD. Candidate, Lake Erie College of Osteopathic Medicine

The EarlyBird study investigated how to predict future pre-diabetes and type 2 diabetes in children.

Years of research have shown us that there are many factors that predispose patients to type 2 diabetes. However, researchers at the University of Plymouth, in collaboration with Nestl Institute of Health Sciences, monitored children to gain more insight into the factors that predispose them to type 2 diabetes in adulthood.TheEarlyBirdstudy, which is a prospective cohort study, investigated the genetic risk markers of type 2 diabetes in healthy children, as well as the influence trajectory of insulin and glucose independently of BMI.

EarlyBirdfollowed 300 children from the ages of 5 to 16 years old to determine who would become at-risk for developing type 2 diabetes, and why.Annual clinical anthropometric and physiological measurements were taken from the children. Researchers were among the first to report an early occurrence of -cell dysfunction in children who later developed pre-diabetes.This study also showed impaired fasting glycemia in subjects by the age of 15 years; these children had previously exhibited high blood glucose levels at the age of 5. The genetic variants, puberty, and weight gain were also analyzed byEarlyBirdto see how these factors could influence insulin action and blood glucose levels at an early age.

Results from this studyproved to be signicant because they reveal the changes in insulin secretion, insulin action, and glycemia over time. Genetic linkage of the SNPs associated with adult diabetes was mirrored in the children in their association with insulin and glycemic traits. SNPs susceptibility also showed age-specic interactions in the child subjects, with some of these traits including: rs780094(GCKR), rs4457053(ZBED3), rs11257655(CDC123), rs12779790 (CDC123 and CAMK1D), rs1111875 (HHEX), rs7178572 (HMG20A), rs9787485 (NRG3), and rs1535500 (KCNK16). Many of the common genetic variants were associated with a variety of high levels of fasting blood glucose.

GCKR and ZBED3 were two intronic genetic variants that were associated with different trajectories of fasting blood glucose from an early age throughout childhood.An increased risk of developing type 2 diabetes showed some correlation from the SNP ZEBD3 through elevated WNT activity.This pathway is controlled by short-chain fatty acids produced during the digestion of dietary fiber. ZEBD3 is known to affect fiber intake, which has led to the belief that this SNP is a relevant genetic maker for children who would benefit from increased consumption of dietary intake. GCKR is believed to be associated with lower fasting blood glucose levels in adults. In this study, it was found that the GCKR genotype was negatively associated with an age-dependent course of glucose; however, children at the age of 5 years old showed a positive association with blood glucose.

One of the most pivotal discoveries in this study is that relative defects in -cell function were a determining factor for who developed pre-diabetes. HOMA-B (-cell function) carried the most genetic associations of diabetes susceptibility. SNPs in the CDC123, HHEXIDE, and KCNK16 loci, showed a negative association with HOMA-B. SNPs in the CDC123 loci may represent that there is-cell mass and can influence function throughout growth. Evidence from theEarlyBirdstudy showed that that the interactions of the SNP in HHEXIDE loci with the trajectories of SHBG, IGF-1, and 17-OHP may inuence endocrine traits and therefore the maturation of other biological processes in childhood.Through these findings, it is believed that insulin action is alsoinuenced by genetic variations in the growth hormoneIGF-1 axis and adrenal and sex steroid activity, with a negative association in both HOMA-B and SHBG (sex hormone-binding globulins). Since the HHEX IDE SNP relates to insulin secretion capacity in early life, it is believed that there are effects beyond fetal development into pubertal growth and development.

TheEarlyBirdstudy was successful in demonstrating that SNPs previously associated with diabetes in adults also can be influential in children with the course of glycemic and insulin traits, independent of BMI.

Practice Pearls:

Carayol, J. et al.(2020) Genetic Susceptibility Determines -Cell Function and Fasting Glycemia Trajectories Throughout Childhood: A 12-Year Cohort Study (EarlyBird76).Diabetes Care.doi.org/10.2337/dc19-0806.

ChardaeWhitner, 2020 PharmD. Candidate, Lake Erie College of Osteopathic Medicine

See more about pre-diabetes in our condition center.

More:

EarlyBird Study: Early Detection of Adult-Onset Type 2 Diabetes in Youth - Diabetes In Control

Robots Everywhere: Machines that grow, cook, and serve food – Digital Trends

The cultivation and production of food are what allowed humans to progress from tribes of hunters/gatherers to be able to develop settlements and cities. Planting, growing, harvesting, and preparing food is the basis of our modern civilizations. Now our abilities to do all of these tasks have progressed so far that many of these steps can be done by robots and machines. So what does the future of robotics look like when it intersects with food production? We take a look at the three main areas in which robots are interacting with the process: During the farming stage, during the processing stage, and during the cooking and serving stage.

When it comes to farming and growing our crops, huge advancements in both hardware and software technologies have allowed farmers to use more and more autonomous machines. Companies like John Deere have developed tractors that run without human involvement, using GPS, camera technology, and myriad sensors to help them tend to each individual plant in their field, from planting to fertilizing to harvesting. This allows farmers to get more done with less manpower.

When it comes to food processing, using machines and automated robots is nothing new. Many of us have seen footage on all sorts of food plants where various machines work to process and package everything from fruit to cake. Breakthroughs in technology have allowed autonomous machines to move beyond simple packaging to being able to individually process complex items like removing bones from fish fillets using various sensors and cameras, and then removing the bones with a water jet spray all in a manner of seconds.

But what about food cooking and serving? Humans still play the biggest role in the preparation and serving of food. Cooking requires a huge amount of nuance, dexterity, and learning, and while robots arent quite up to speed with dealing with the complexities of cooking, they are making quite the leap forward. There are machines that can cook omelets, make stir fry, flip burgers, and more, using advanced sensors, cameras, temperature gauges, and machine learning.

The idea in all of this is not to replace human workers but to make the process more efficient and cost-effective. By allowing robots and automated machines to work alongside us at every step of the process can result in making food cheaper, healthier, and more accessible to everyone.

More:

Robots Everywhere: Machines that grow, cook, and serve food - Digital Trends

What Organisational Changes are Required to Succeed with Robotics Process Automation? – Analytics Insight

What Organisational Changes are Required to Succeed with Robotics Process Automation?

Ever wondered what makes an RPA solution fall short of its potential? Implementation complexity may just be the answer!

Robotic Process Automation (RPA) is the buzzword that has caught business attention and is the new buzzword, that enterprises have embraced. To make automation successful, enterprises need to make changes in their vision and strategy. RPA is more than just automation and replacing people with technology rather it involves process design which must be the core of the business strategy.

RPA mitigates rule-based processes to automate it resulting in tremendous process improvement that reduces process costs by nearly 80 percent but only when the right capabilities and teams are put in place. RPA leaders tend to overestimate the speed of RPA implementation, which may lead to difficulties handling resources, managing expectations, and capturing targeted ROIs.

The need of the hour is prudent leaders who have a clear vision of the future that comes with realistic expectations based on a deep understanding of technology. RPA leaders must distinguish wins from full-scale RPA implementations. This helps in keeping teams motivated by allocating resources based on need.

Businesses have typically turned on to third-party service providers that develop bots, but may fall back in training internal employees who are charged with crucial maintenance and solution upgrades. This makes employees who are not familiar with code, process design, or assumptions for effective functioning. Besides, there needs to be a deliberate and clear knowledge transfer between maintenance teams and bot developers. Costs of neglecting may run high since teams spend more time on bot maintenance which means realising fewer-than-anticipated benefits from the deployed bots.

Many enterprises select members of their RPA team based on domain knowledge and their technical prowess. They underestimate the need for the RPA team to work with other domains of the organization. Making sure the project is in full alignment with IT requires team members who meet IT expectations on a regular basis. This responsibility might be best delegated to someone who has deep existing relationships within the enterprise coupled with management skills than to someone whose expertise is technology.

Similarly, on the business side, an RPA team must go beyond just producing bots for the business to effectively address business concerns around change-management efforts and service level agreements (SLAs). These translators track bot performance against business goals to communicate additional requirements to the RPA teams for a smooth transition across enterprises.

Share This ArticleDo the sharing thingy

About AuthorMore info about author

Kamalika Some is an NCFM level 1 certified professional with previous professional stints at Axis Bank and ICICI Bank. An MBA (Finance) and PGP Analytics by Education, Kamalika is passionate to write about Analytics driving technological change.

Read the rest here:

What Organisational Changes are Required to Succeed with Robotics Process Automation? - Analytics Insight

Can a systematic usability evaluation help us develop better wearable robots? – On Medicine – BMC Blogs Network

Jan T. Meyer, Olivier Lambercy & Roger Gassert, 2020

Wearable robotics has gained increasing attention over the past years. The human-centered design paradigms for these wearable robotics aim to promote technology acceptance by better considering the needs of the end-user. Through workshops, focus groups, and participatory design sessions, developers strive to meet user needs and develop the next-generation wearable robotics technology that can improve the quality of life of millions. However, low technology acceptance and adoption of wearable robots for sensorimotor therapy, assistance in daily life, work-related injury prevention, or human augmentation indicates that state-of-the-art devices still underperform in real-life usability.

freshidea / stock.adobe.com

While there is a consensus that usability is key, publications on dedicated and systematic usability studies combining quantitative and qualitative evaluation are scarce (Reinkensmeyer 2019). The evident lack of standards on how to best evaluate usability in wearable robotics directly affects research, technology maturation, and the ability to compare results and technologies (Shore 2018, Armansdottir et al. 2020). Thus, we believe that it is of fundamental importance to understand current development and evaluation practices in more detail, identify their limitations, and learn which evaluation methods have helped to generate solutions with high usability.

technological solutions that not only meet the target users needs, but may even exceed their expectations.

With a survey devoted to usability evaluation in wearable robotics, we aim to investigate how usability is defined, how developers perceive its importance, how the evaluation focus may shift during technology maturation, and how target-user feedback is acquired. With these insights, we aim to guide researchers/developers in the process of identifying the right measures for their specific context of use, and consequently, support ongoing endeavors in establishing benchmarking practices.

We believe that a more structured and comparable evaluation will enable a genuinely human-centered design of wearable robots and hopefully contribute to the development of technological solutions that not only meet the target users needs, but may even exceed their expectations.

Read the original here:

Can a systematic usability evaluation help us develop better wearable robots? - On Medicine - BMC Blogs Network

GreyOrange receives first-ever certification for robots in commercial and industrial environments – Modern Materials Handling

GreyOrange, a global software and mobile robotics provider that leverages artificial intelligence and machine learning to optimize fulfillment operations, announced that one of its autonomous mobile robots, Ranger GTP, is the first Automated Mobile Platforms (AMP) robot of its kind to be UL Certified to UL 3100, Second Edition for use in commercial and industrial environments.

Ranger GTP is a goods-to-person autonomous mobile robot that can transport inventory from 220 to 3,500 pounds to workers for picking and packing, while working in collaborative performance with other robots and the human workforce.

This highly sought-after certification demonstrates GreyOranges leadership in setting the bar for safety of automated fulfillment in warehouse environment, said Akash Gupta, Chief Technology Officer, GreyOrange. We felt it was important to develop a truly safer product that would inspire trust and assure our customers and partners that they have made the right decision by implementing a GreyOrange solution.

Ranger series robots, including Ranger GTP, are built together with GreyMatter AI software to form the GreyOrange Fulfillment Operating System. GreyOrange Ranger robots continuously communicate with each other and GreyMatter to recalculate and orchestrate fulfillment priorities and inventory movement patterns based on real-time factors. Ranger GTP is certified against fire, electrical and other hazards, helping to make it safe for both humans and robots to work with.

We are pleased to see GreyOrange proactively achieve UL Certification for Ranger GTP AMP to UL 3100, Second Edition, said Jeff Smidt, vice president and general manager of energy and power technologies at UL. This represents a milestone in industry by heading down a safer path for automated mobile platforms.

UL Certified products go through rigorous testing, inspection and auditing in the industrial field, where risk is higher than most and safety is the utmost important application. The certification process included a step-by-step review of all the components in Ranger GTP from a fire and shock perspective to meet the safety requirements of UL 3100, Second Edition, Outline of Investigation for Automated Mobile Platforms (AMPs).

Read the original post:

GreyOrange receives first-ever certification for robots in commercial and industrial environments - Modern Materials Handling

Mayo in Mankato adds more robotic surgery options – Mankato Free Press

Surgeons say the continued expansion of robotic surgery options at Mayo Clinic Health System in Mankato will allow for more minimally invasive procedures.

The health system recently added a new DaVinci Xi robot for the urology, gynecology and general surgery departments. The orthopedic surgery department also received a new robot this week.

Surgical staff will train to use the latest technology, with the DaVinci set to debut in August.

It actually gives us a lot more versatility with what we can do, said Dr. Tara Krosch, a general and trauma surgeon, of the new technology. The focus is still the same though, to allow for more minimally invasive surgeries.

Krosch is also vice chair of the health systems clinical practice in surgical specialties. She said Mayo in Mankato went from having two surgeons using robotic surgery to nine over about the last two years.

One of the nine surgeons, Dr. Derek Gearman, joined the team last year to provide prostate surgeries. His arrival meant Mayo in Mankatos patients no longer needed to go Rochester for the treatment like they had in past years.

Gearmans robotic surgery capabilities include the partial or complete removal of prostates, removing cancerous tumors from kidneys and reconstructing the renal pelvis. Bringing care options not previously available at the hospital is a great feeling, he said.

Just knowing they can be taken care of at a high level closer to where they live is beneficial, he said.

He and Krosch said they expect robotics to play an increasingly big role in surgeries as time goes on. Gearman noted the vast majority of trainees coming through his residency program were more proficient in using robots for procedures like prostatectomies.

Especially in a narrow part of the body like the pelvis, he said the robots enhanced visualization helps surgeons reach difficult areas. It also allows for smaller incisions, contributing to less severe pain and less need for pain medication afterward.

Its wildly beneficial for patients, and the biggest area I see it is post-operative time and narcotic use, Gearman said. This is a way to hopefully avoid even needing to prescribe those types of medications.

He also uses another technological advancement, lasers, for a different prostate procedure. Holmium laser prostate surgery, or HoLEP, involves removing the tissue blocking urine flow through the prostate.

It requires no incisions, and Gearman is one of just two surgeons in the Midwest to offer it. The other is at the University of Minnesota.

Gearman said hes had patients who thought theyd never be able to urinate without a catheter again receive the procedure and have near-instantaneous benefits.

Now with the new, DaVinci robot set to get its first use later this month, he called it a huge upgrade from the previous model. Itll have sharper visualizations, better software and more instruments, he said.

The robot to be used for orthopedic surgery, a Mako, came Thursday. A start date for using it isnt yet set, since staff still need to go through training.

Krosch sees it bringing similar benefits once up and running. In some cases, the more minimally invasive procedures can get patients in for surgery and back home to recover within the same day, she said.

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

See the original post:

Mayo in Mankato adds more robotic surgery options - Mankato Free Press

Global Programmable Robots market is expected to reach $8,083.61 million by 2027 – PRNewswire

GAITHERSBURG, Md., July 29, 2020 /PRNewswire/ -- According to Stratistics MRC, the Global Programmable Robots Market is accounted for $2,302.07 million in 2019 and is expected to reach $8,083.61 million by 2027 growing at a CAGR of 17.0% during the forecast period.

Some of the key players profiled in the Programmable Robots Market include Aldebaran Robotics Sas, Fischertechnik GmbH, Honda Motor Co., Ltd, Innovation First International Inc, iRobot Corporation, Modular Robotics Incorporated, Orbotix, Inc, RoboBuilder Co. Ltd, SoftBank Robotics Europe SAS, SuperDroid Robots Inc., The LEGO Group, and Wowwee Group Limited (Optimal Group Inc.).

Increasing adoption of robots for educational purposes and continuous innovation leading to better functionality of robots are the major factors propelling the market growth. However, high cost and time-consuming implementation are hampering the market growth.

Request for sample here: https://www.strategymrc.com/report/programmable-robots-market-outlook/request-sample

Programmable robots are types of automatic devices that normally perform functions ascribed through remote controls or specified programs. These programmable robotic kits range from PC-controlled robots to simple remote-controlled robots and further from complex robots such as humanoids to simple wheeled robots. The programmable robot is an automatic device that performs functions normally ascribed though programs or remote control. These robots help in understanding and conceptualizing the theories involved in designing and operating a robot and also help to program the robot using simple virtual programming languages such C, C++, The major consumers of these robots are students, hobbyists, and researchers.

Based on the application, the education segment is going to have a lucrative growth during the forecast period owing to the increasing adoption of programmable robots for educational purpose to enhance the learning and teaching process. Programmable robots in education help students to engage highly in the four subject areas namely science, technology, engineering and mathematics (STEM). It helps students to learn via project-based learning, hands-on learning, collaborative learning, authentic learning, and constructive learning approaches which stimulates the learning process.

Access the complete report at: https://www.strategymrc.com/report/programmable-robots-market-outlook

By geography, Asia Pacific is anticipated to hold considerable market share during the forecast period due to the rising awareness about the benefits of robotics and escalating adoption of robotic kits in the region. The Asia Pacific will emerge as the leading market in terms of growth owing to the growing demand from countries such as India, China, and Japan. Also, the increasing adoption of robotic kits in schools, universities, and research institutes for educational purpose is another reason driving the growth of a programmable robot market in the region.

Make an inquiry at: https://www.strategymrc.com/report/programmable-robots-market-outlook

Types Covered:

Components Covered:

Applications Covered:

Regions Covered:

What our report offers:

Follow us on Twitter:https://twitter.com/StratisticsMRC

Follow us on LinkedIn at:https://www.linkedin.com/company/stratistics-market-research-consulting-pvt-ltd?trk=mini-profile

About Stratistics MRC

We offer a wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services, and Full-Time Equivalent (FTE) services in the research world. We explore market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends.

Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects.

Contact Info:

Name: Srikant Reddy Email:[emailprotected] Organization: Stratistics Market Research Consulting Pvt Ltd Phone: +1-301-202-5929 Website:https://www.strategymrc.com

SOURCE Stratistics Market Research Consulting Pvt Ltd

http://www.strategymrc.com/

See original here:

Global Programmable Robots market is expected to reach $8,083.61 million by 2027 - PRNewswire

Trending News Corona impact on Household Robots Market Advanced Technologies and Growth Opportunities in Industry 2020-2025| Intuitive Surgical,…

Global Household Robots Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)

The global Household Robots Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Household Robots Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Household Robots Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Household Robots Market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Household Robots Market.

Leading players of the global Household Robots Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Household Robots Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Household Robots Market. It also provides useful recommendations for new as well as established players of the global Household Robots Market.

Final Household Robots Report will add the analysis of the impact of COVID-19 on this Market.

Household Robots Market competition by top manufacturers/Key player Profiled:Intuitive Surgical, Irobot, Neato Robotics, Sharp, Dyson, Toshiba, Panasonic, F&P Robotics, Jibo, Savioke, SoftBank, Ecovacs, Fujitsu, Siasun Robot & Automation, Samsung, Yujin Robot, Matsutek, LG

>>> Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Household Robots Market:

the global Household Robots market is estimated to be valued at XX Million US$ in 2019 and is projected to reach XX Million US$ by 2026, expanding at a CAGR of XX% during the forecast period. The report on Household Robots market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, industrial chain, etc. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Household Robots.

Segmentation by Product:

Floor Cleaning RobotsWindow Cleaning RobotsPool Cleaning Robots

Segmentation by Application:

IndividualCommercial

Competitive Analysis:

Global Household Robots Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Household Robots Market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Scope of the Report:The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Household Robots Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

The report offers in-depth assessment of the growth and other aspects of the Household Robots market in important countries (regions), including:

North America(United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2395223

Table of Contents

Report Overview:It includes major players of the global Household Robots Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Household Robots Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Household Robots Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Household Robots Market by application, it gives a study on the consumption in the global Household Robots Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Household Robots Market are profiled in this section. The analysts have provided information about their recent developments in the global Household Robots Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Household Robots Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Household Robots Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Household Robots Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

See more here:

Trending News Corona impact on Household Robots Market Advanced Technologies and Growth Opportunities in Industry 2020-2025| Intuitive Surgical,...

COVID-19 will have lasting effects on providers, including how they operate and how they’re paid – Modern Healthcare

Its almost paradoxical that healthcare has been one of the hardest hit industries within the U.S. during the global COVID-19 pandemic. Unanticipated impacts on patient care and medical practice operations will be felt for years to come.

From the delay of preventive care and non-emergency procedures and surgeries to the rapid adoption of telehealth to volatile patient volumes, we know that how we engage and compensate healthcare providers will continue to shift, but leading with a strategy of hoping we will return to the healthcare industry that we once knew will fail.

The near future remains vague. However, we know that we need more healthcare providersand not just because of COVID-19. Our nation is facing a demographic shift to a sicker and older population. We have an upcoming election that will challenge us to choose a healthcare future based on the political ideology that best represents our personal experiences with the COVID-19 pandemic. Our healthcare workers are suffering more than ever from stress and mental health issuesburning out at alarming rates. While well-trained providers are vital to healthcare systems, the rapid changes from the pandemic have had dire effects on these individuals.

While front-line providers cared for COVID-19 patients, operations essentially halted for medical practices that were providing nonessential care. The COVID-19 crisis has had significant effects on medical practices of all sizes and specialties. A COVID-19 financial impact report by the Medical Group Management Association found that, on average, practices reported a 55% decrease in revenue and 60% decrease in patient volumes since the pandemic began. These decreases prompted decisions to furlough employees in an effort to avoid layoffs. In April 2020 alone, 1.4 million healthcare workers were furloughed. We have begun to see how COVID-19 is affecting medical practices financial viability.

This past spring, many medical practices re-opened to see patients in person. The increase of office visits amid lifting stay-at-home orders offered a glimmer of hope, but medical practices remain a long way from returning to normal. More than 60% of healthcare leaders reported their compensation has dropped during the pandemic, according to a June MGMA Stat poll. While the CARES Act will provide short-term relief, the implications will be felt for years. At a minimum, healthcare jobs and compensation will not return to anything close to normal until at least mid-to-late 2021. At best, we will see organizations hold off on annual pay increases for the next one to three years as they try to regain normalcy. At worst, we will see organizations decrease their workforces so they can decrease payroll, which is their largest operating expense.

Prior to the pandemic, compensation for physicians, providers other than physicians, nurses and other general and senior management positions was steadily increasing. According to Modern Healthcare, physician compensation was creeping upward in 2019. Most specialties saw 2% to 3% compensation gains, largely due to productivity. In 2020, some of the larger health systems started asking how to realign their compensation models now that those that were primarily volume-based have crashed.

Many healthcare employers that previously considered shifting away from fee-for-service to productivity-based models are actively planning to make that leap. With shifting demands on healthcare providers, the ongoing path to value-based care and the state of our healthcare industry overall, we can plan on compensation models looking different in a post COVID-19 world.

Where do we start the journey to align new compensation models? We start with what we know and build from there.

Healthcare organizations can use the compensation data from before the pandemic as a building block for the future. It is also crucial to understand that there is opportunity in a future that we design, including new compensation models that align us with our new challenges and goals. The only certainty is that COVID-19 is going to facilitate change in traditional healthcare provider compensation models now and into the future.

More here:

COVID-19 will have lasting effects on providers, including how they operate and how they're paid - Modern Healthcare